ProCE Banner Activity

Key NAFLD/NASH Studies Influencing My Practice Following EASL 2019

Audio

Listen as expert faculty discusses the clinical impact of the most important NAFLD/NASH data from the Vienna meeting.

Released: May 02, 2019

Expiration: April 30, 2020

No longer available for credit.

Share

Faculty

Zobair M. Younossi

Zobair M. Younossi, MD, MPH, FACP, FACG

Executive Director, Center for Liver Diseases
Inova Fairfax Hospital
Executive Director of Research
Inova Health System
Professor of Medicine
Virginia Commonwealth University, Inova Campus
Annandale, Virginia

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Gilead

Faculty Disclosure

Primary Author

Zobair M. Younossi, MD, MPH, FACP, FACG

Executive Director, Center for Liver Diseases
Inova Fairfax Hospital
Executive Director of Research
Inova Health System
Professor of Medicine
Virginia Commonwealth University, Inova Campus
Annandale, Virginia

Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD, has disclosed that he has received consulting fees or funds for research support from Allergan, Bristol-Myers Squibb, Echosens, Gilead Sciences, Intercept, Merck, Novartis, Novo Nordisk, Quest Diagnostics, Shinogi, Terns, and Viking.